Cetuximab (Erbitux) — What You Need to Know Before You Start

For colorectal cancer, cetuximab only works when the tumour does not carry a RAS mutation. When a RAS mutation is present, the cell's growth signal continues even if EGFR is blocked — the pathway is activated further inside the cell, bypassing the point where cetuximab acts. Giving cetuximab to a RAS-mutant tumour exposes you to real side effects with no realistic prospect of benefit, which is why NCCN, ASCO and ESMO all recommend testing before prescribing. The result comes from your tumour tissue, not your personal genetics. Your oncologist will have it before recommending cetuximab.

A moderate rash is often, though not always, associated with the drug reaching its target. EGFR is present in skin cells as well as tumour cells, and when cetuximab blocks it in both, skin changes follow. The association has been noted in clinical literature reviewed by ASCO and ESMO, but it is not an absolute indicator — response is assessed by imaging, not by the skin. The practical point is to report the rash accurately at every appointment, because its severity can influence whether the dose needs adjustment.

Yes, and your team will give you specific advice for your skin. General guidance from dermatology and oncology sources includes moisturising frequently with a fragrance-free, alcohol-free cream, applying sunscreen before going outdoors, and avoiding abrasive scrubs or strongly medicated products on affected skin. Do not use over-the-counter acne treatments without asking your team first — the cetuximab rash is not caused by bacteria, and those products can irritate already-sensitive skin. If the skin becomes broken, weepy or looks infected, tell your team the same day.

Yes. Blood tests throughout treatment will include magnesium. Cetuximab can reduce the kidneys' ability to hold on to magnesium, and if levels fall you may notice muscle cramps, weakness or an irregular heartbeat — tell your team if you notice any of these between appointments. Low magnesium is manageable: your team may prescribe supplements by mouth or give you a magnesium infusion alongside cetuximab. This is a predictable effect that routine monitoring is designed to catch early.

No. Both are given by infusion and both are sometimes described as targeted, which causes confusion. Cetuximab is a monoclonal antibody that blocks a specific protein on the surface of cancer cells. Checkpoint inhibitors — drugs such as pembrolizumab or nivolumab — work by releasing the brakes on your own immune system. The two approaches have different mechanisms, different side-effect profiles and different eligibility criteria. If your oncologist has recommended cetuximab, it is because EGFR is the relevant target for your cancer, not because activating the immune system is the goal.

Contact your team the same day if the rash becomes broken, rapidly spreading or looks infected; if you have a fever; if you experience chest tightness, shortness of breath, or swelling of the face or throat during or after an infusion; or if you notice muscle cramps or an irregular heartbeat that might suggest low magnesium. Between appointments, note how the rash is changing and any new symptoms, because your team will ask at each visit. You do not need to wait for a scheduled appointment if something is worrying you — the contact number will be given to you at your first infusion.